160 related articles for article (PubMed ID: 33558179)
1. Cost-effectiveness of endocrine therapy versus radiotherapy versus combined endocrine and radiotherapy for older women with early-stage breast cancer.
Wheeler SB; Rotter JS; Baggett CD; Zhou X; Zagar T; Reeder-Hayes KE
J Geriatr Oncol; 2021 Jun; 12(5):741-748. PubMed ID: 33558179
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years or older.
Ward MC; Vicini F; Al-Hilli Z; Chadha M; Pierce L; Recht A; Hayman J; Thaker N; Khan AJ; Keisch M; Shah C
Breast Cancer Res Treat; 2020 Jul; 182(2):355-365. PubMed ID: 32468336
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial.
Liljegren G; Karlsson G; Bergh J; Holmberg L
Ann Oncol; 1997 Aug; 8(8):757-63. PubMed ID: 9332683
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer.
Deshmukh AA; Shirvani SM; Lal L; Swint JM; Cantor SB; Smith BD; Likhacheva A
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059428
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
[TBL] [Abstract][Full Text] [Related]
7. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of MammaPrint
Luyendijk M; Jager A; Buijs SM; Siesling S; Groot CAU; Blommestein HM
Pharmacoeconomics; 2023 Aug; 41(8):981-997. PubMed ID: 37245167
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.
Thompson D; Taylor DC; Montoya EL; Winer EP; Jones SE; Weinstein MC
Value Health; 2007; 10(5):367-76. PubMed ID: 17888101
[TBL] [Abstract][Full Text] [Related]
10. Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation.
Ward MC; Vicini F; Chadha M; Pierce L; Recht A; Hayman J; Thaker NG; Khan A; Keisch M; Shah C
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):296-306. PubMed ID: 31212043
[TBL] [Abstract][Full Text] [Related]
11. Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomized trial. Uppsala-Orebro Breast Cancer Study Group.
Liljegren G; Holmberg L; Adami HO; Westman G; Graffman S; Bergh J
J Natl Cancer Inst; 1994 May; 86(9):717-22. PubMed ID: 8158702
[TBL] [Abstract][Full Text] [Related]
12. Examining the cost-effectiveness of radiation therapy among older women with favorable-risk breast cancer.
Sen S; Wang SY; Soulos PR; Frick KD; Long JB; Roberts KB; Yu JB; Evans SB; Chagpar AB; Gross CP
J Natl Cancer Inst; 2014 Mar; 106(3):dju008. PubMed ID: 24598714
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA; Millward MJ
Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
[TBL] [Abstract][Full Text] [Related]
14. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
15. Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: a cost-effectiveness analysis.
Sher DJ; Wittenberg E; Suh WW; Taghian AG; Punglia RS
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):440-6. PubMed ID: 18963542
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.
Delea TE; Taneja C; Sofrygin O; Kaura S; Gnant M
Clin Breast Cancer; 2010 Aug; 10(4):267-74. PubMed ID: 20705558
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women.
Lairson DR; Parikh RC; Cormier JN; Chan W; Du XL
Value Health; 2015 Dec; 18(8):1070-8. PubMed ID: 26686793
[TBL] [Abstract][Full Text] [Related]
19. The INTRABEAM® Photon Radiotherapy System for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation.
Picot J; Copley V; Colquitt JL; Kalita N; Hartwell D; Bryant J
Health Technol Assess; 2015 Aug; 19(69):1-190. PubMed ID: 26323045
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
